# A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

> **NCT02409186** · PHASE3 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 200 (estimated)

## Conditions studied

- Prosthesis Survival

## Interventions

- **DRUG:** Nimotuzumab
- **RADIATION:** radiotherapy
- **DRUG:** chemoradiotherapy Paclitaxel
- **DRUG:** chemoradiotherapy Cisplatin
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT02409186
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2017-12
- **Final completion:** 2021-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2016-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02409186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02409186, "A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02409186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*